Antipsychotic dosing: extended, and transient.

@article{Seeman2012AntipsychoticDE,
  title={Antipsychotic dosing: extended, and transient.},
  author={P. Seeman and G. Remington},
  journal={Clinical schizophrenia & related psychoses},
  year={2012},
  volume={6 2},
  pages={
          86-7
        }
}
  • P. Seeman, G. Remington
  • Published 2012
  • Medicine
  • Clinical schizophrenia & related psychoses
    • New Ways of Antipsychotic Dosing Considering the few new medications being developed for schizophrenia, it is recognized that novel avenues of research are needed for drug treatment of schizophrenia. While current antipsychotic drugs primarily block dopamine D2 receptors or interfere with dopamine neurotransmission (1, 2), many drugs for non-D2 pathways and receptors have been tested as possible antipsychotics, but not with much success. These include antagonists or agonists at receptors for D1… CONTINUE READING
    View on PubMed
    doi.org
    1 Citations
    Background Citations
    1
    One Citation
    Citation Type

    Citation Type

    Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials
    • 11

    References

    SHOWING 1-10 OF 15 REFERENCES
    Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
    • 238
    • PDF
    Dopamine D2 receptors as treatment targets in schizophrenia.
    • P. Seeman
    • Medicine
    • Clinical schizophrenia & related psychoses
    • 2010
    • 152
    Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
    • 953
    • PDF
    A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    • 381
    • PDF
    Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
    • 652
    • PDF
    Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia
    • 14
    A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia
    • 27
    "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.
    • 54
    A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
    • 210
    Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol
    • 85